Local and systemic administration of activating anti-CD40 antibody either alone or in conjunction with other therapies has been shown to alter the phenotype of DC subsets and augment tumor specific CD8+ T-cell responses in vivo [8, 100–103]. This evidence concerns the gene CD8A and neoplasm.